Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Adverse pregnancy outcomes associated with treatment for CIN; Prevention of egg allergy in infants

Date Released: Feb 22 2017

This episode features Dr. Barbara Goff, discussing a population-based study on adverse pregnancy outcomes associated with treatment for cervical intraepithelial neoplasia (CIN) (starts at 00:43); and Dr. David Fleischer, discussing data on early dietary egg introduction for the prevention of egg allergy in infants (starts at 15:32).

Listen to the full podcast by pressing the Play Button below, or jump to the segment on adverse pregnancy outcomes associated with treatment for CIN, or the segment on prevention of egg allergy in infants.

Dr. GoffDr. Barbara Goff is a Professor of Obstetrics and Gynecology and Director of the Division of Gynecologic Oncology at the University of Washington School of Medicine.
Dr. FleischerDr. David Fleischer is an Associate Professor of Pediatrics and Allergy at the University of Colorado School of Medicine and Director of the Food Challenge Unit at Children’s Hospital Colorado.

Segment on adverse pregnancy outcomes associated with treatment for CIN (Dr. Goff):

  1. Bjørge T, Skare GB, Bjørge L, et al. Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstet Gynecol 2016; 128:1265.

Segment on prevention of egg allergy in infants (Dr. Fleischer):

  1. Natsume O, Kabashima S, Nakazato J, et al. Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 389:276.
  2. Palmer DJ, Sullivan TR, Gold MS, et al. Randomized controlled trial of early regular egg intake to prevent egg allergy. J Allergy Clin Immunol 2016.
  3. Wei-Liang Tan J, Valerio C, Barnes EH, et al. A randomized trial of egg introduction from 4 months of age in infants at risk for egg allergy. J Allergy Clin Immunol 2016.
  4. Bellach J, Schwarz V, Ahrens B, et al. Randomized placebo-controlled trial of hen's egg consumption for primary prevention in infants. J Allergy Clin Immunol 2016.

Close

Barbara Goff, MD Consultant/Advisory Boards: Roche Diagnostics [Biomarkers for ovarian cancer (HE4)]. Employment (Spouse): Lilly [General oncology (Gemcitabine, pemetrexed)] - No relevant conflict on topics.

David M Fleischer, MD Grant/Research/Clinical Trial Support: Monsanto Company [Food allergy]; Nestle Nutrition Institute [Food allergy]; DBV Technologies [Food allergies (Electrostatic immunotherapy patch)]; Aimmune Therapeutics [Food allergies (oral immunotherapy)]. Speaker's Bureau: Nestle Nutrition Institute [Food allergy]. Consultant/Advisory Boards: NIAID Coordinating Committee and Expert Panel, Update to the Food Allergy Guidelines, Prevention of Peanut Allergy [Food allergy]; Medical Advisory Board for the Food Allergy & Anaphylaxis Connection Team (FAACT) [Food allergy]; Medical Advisory Board for FARE [Food allergy]; Medical Advisory Council for the National Peanut Board [Food allergy]; DBV Technologies [Food allergy]’; Aimmune Therapeutics [Food allergy]; Intrommune Therapeutics [Food allergy]; Kaleo Pharma [Food allergy].

Pages